IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model: Role of Both IL-1α and IL-1β

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 12, 2015, Pages 2605-2616

  Lee, Youngho ^a   Wakita, Daiko ^a   Dagvadorj, Jargalsaikhan ^a   Shimada, Kenichi ^a   Chen, Shuang ^a   Huang, Ganghua ^a   Lehman, Thomas J A ^b   Fishbein, Michael C ^c   Hoffman, Hal M ^d   Crother, Timothy R ^a   Arditi, Moshe ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

dendritic cells; Endothelial cells; interleukin 1; mucocutaneous lymph node syndrome; MyD88; protein

Indexed keywords

GLYCOPROTEIN P 15095; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; AIM2 PROTEIN, MOUSE; CARRIER PROTEIN; CRYOPYRIN; DNA BINDING PROTEIN; IL1B PROTEIN, MOUSE; IL1R1 PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA CONVERTING ENZYME; MYD88 PROTEIN, MOUSE; NLRP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERITIS; ARTICLE; BACTERIAL CELL WALL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DEPLETION; HEMATOPOIETIC CELL; KNOCKOUT MOUSE; LACTOBACILLUS CASEI; MACROPHAGE; MOUSE; MOUSE MODEL; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; ANIMAL; AORTA; AORTITIS; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; CELL WALL; CHEMICALLY INDUCED; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; DISEASE MODEL; ENDOTHELIUM CELL; GENETICS; HISTOCOMPATIBILITY; METABOLISM; PATHOLOGY;

ANIMALS; AORTA; AORTITIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CARRIER PROTEINS; CASPASE 1; CELL WALL; CELLS, CULTURED; CORONARY ARTERY DISEASE; CORONARY VESSELS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; LACTOBACILLUS CASEI; MACROPHAGES; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYELOID DIFFERENTIATION FACTOR 88; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RECEPTORS, INTERLEUKIN-1 TYPE I; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSPLANTATION CHIMERA;

EID: 84948087756     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306475     Document Type: Article

References (79)

1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.
2. Rowley AH, Baker SC, Shulman ST, Garcia FL, Fox LM, Kos IM, Crawford SE, Russo PA, Hammadeh R, Takahashi K, Orenstein JM. RNAcontaining cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS One. 2008;3:e1582. doi: 10.1371/journal.pone.0001582.
3. Rowley AH, Shulman ST, Garcia FL, Guzman-Cottrill JA, Miura M, Lee HL, Baker SC. Cloning the arterial IgA antibody response during acute Kawasaki disease. J Immunol. 2005;175:8386-8391.
4. Onouchi Y, Ozaki K, Burns JC, et al; Japan Kawasaki Disease Genome Consortium; US Kawasaki Disease Genetics Consortium. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012;44:517-521. doi: 10.1038/ng.2220.
5. Shimizu C, Matsubara T, Onouchi Y, et al. Matrix metalloproteinase haplotypes associated with coronary artery aneurysm formation in patients with Kawasaki disease. J Hum Genet. 2010;55:779-784. doi: 10.1038/jhg.2010.109.
6. Rowley AH, Baker SC, Orenstein JM, Shulman ST. Searching for the cause of Kawasaki disease-cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol. 2008;6:394-401. doi: 10.1038/nrmicro1853.
7. Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015;11:475-482. doi: 10.1038/nrrheum.2015.54.
8. Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010;29:483-488. doi: 10.1097/INF.0b013e3181cf8705.
9. Burns JC. Kawasaki Disease update. Indian J Pediatr. 2009;76:71-76. doi: 10.1007/s12098-009-0031-3.
10. Newburger JW, Takahashi M, Gerber MA, et al; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease; Council on Cardiovascular Disease in the Young; American Heart Association; American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747-2771. doi: 10.1161/01. CIR.0000145143.19711.78.
11. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364:533-544. doi: 10.1016/S0140-6736(04)16814-1.
12. Orenstein JM, Shulman ST, Fox LM, Baker SC, Takahashi M, Bhatti TR, Russo PA, Mierau GW, de Chadarévian JP, Perlman EJ, Trevenen C, Rotta AT, Kalelkar MB, Rowley AH. Three linked vasculopathic processes characterize Kawasaki disease: a light and transmission electron microscopic study. PLoS One. 2012;7:e38998. doi: 10.1371/journal.pone.0038998.
13. Gupta-Malhotra M, Gruber D, Abraham SS, et al. Atherosclerosis in survivors of Kawasaki disease. J Pediatr. 2009;155:572-577. doi: 10.1016/j.jpeds.2009.04.054.
14. Fukazawa R. Long-term prognosis of Kawasaki disease: increased cardiovascular risk Curr Opin Pediatr. 2010;22:587-592. doi: 10.1097/MOP.0b013e32833e12f7.
15. Paredes N, Mondal T, Brandaõ LR, Chan AK. Management of myocardial infarction in children with Kawasaki disease. Blood Coagul Fibrinolysis. 2010;21:620-631. doi: 10.1097/MBC.0b013e32833d6ec2.
16. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144-1148.
17. Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield JR, Martin DD, Newburger JW, Burns JC. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr. 2008;153:117-121. doi: 10.1016/j.jpeds.2007.12.021.
18. Rowley AH. Finding the cause of Kawasaki disease: a pediatric infectious diseases research priority. J Infect Dis. 2006;194:1635-1637. doi: 10.1086/509514.
19. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease. A 10-to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379-1385.
20. Lehman TJ, Walker SM, Mahnovski V, McCurdy D. Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum. 1985;28:652-659.
21. Myones BL, Bathoria JM, Lehman TJ, Shulman ST. Human IVIG inhibits Lactobacillus casei-inducible coronary arteritis in a murine model. Proceedings of the V International Kawasaki Disease Symposium. Elsevier Science: Fukuoka, Japan. 1995:252-256.
22. Schulte DJ, Yilmaz A, Shimada K, Fishbein MC, Lowe EL, Chen S, Wong M, Doherty TM, Lehman T, Crother TR, Sorrentino R, Arditi M. Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease. J Immunol. 2009;183:5311-5318. doi: 10.4049/jimmunol.0901395.
23. Lehman TJA, Sherry B, Gietl DM, Nguyen HT, Cerami A. Suppression of lactobacillus casei cell wall-induced coronary arteritis in mice by antibody to murine tumor necrosis factor. Proceedings of the Third International Conference on Kawasaki Disease. Elsevier Science: Tokyo, Japan. 1988:203-206.
24. Yilmaz A, Rowley A, Schulte DJ, Doherty TM, Schröder NW, Fishbein MC, Kalelkar M, Cicha I, Schubert K, Daniel WG, Garlichs CD, Arditi M. Activated myeloid dendritic cells accumulate and co-localize with CD3+ T cells in coronary artery lesions in patients with Kawasaki disease. Exp Mol Pathol. 2007;83:93-103. doi: 10.1016/j.yexmp.2007.01.007.
25. Takahashi K, Oharaseki T, Yokouchi Y, Naoe S, Saji T. Kawasaki disease: basic and pathological findings. Clin Exp Nephrol. 2013;17:690-693. doi: 10.1007/s10157-012-0734-z.
26. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis. 2001;184:940-943. doi: 10.1086/323155.
27. Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, Galliani CA, Takahashi K, Naoe S, Kalelkar MB, Crawford SE. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis. 2000;182:1183-1191. doi: 10.1086/315832.
28. Rosenkranz ME, Schulte DJ, Agle LM, Wong MH, Zhang W, Ivashkiv L, Doherty TM, Fishbein MC, Lehman TJ, Michelsen KS, Arditi M. TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation. 2005;112:2966-2973. doi: 10.1161/CIRCULATIONAHA.105.537530.
29. Lee Y, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, Fishbein MC, Lehman TJ, Arditi M. Interleukin-1 is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125:1542-1550. doi: 10.1161/CIRCULATIONAHA.111.072769.
30. Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2014;12:26. doi: 10.1186/1546-0096-12-26.
31. Cohen S, Tacke CE, Straver B, Meijer N, Kuipers IM, Kuijpers TW. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis. 2012;71:2059-2061. doi: 10.1136/annrheumdis-2012-201658.
32. Uchida K, Satoh M, Inoue G, Onuma K, Miyagi M, Iwabuchi K, Takaso M. Cd11c+ macrophages and levels of tnf-alpha and mmp-3 are increased in synovial and adipose tissues of osteoarthritic mice with hyperlipidemia. Clin Exp Immunol. 2015.
33. Motomura Y, Kanno S, Asano K, Tanaka M, Hasegawa Y, Katagiri H, Saito T, Hara H, Nishio H, Hara T, Yamasaki S. Identification of pathogenic cardiac cd11c+ macrophages in nod1-mediated acute coronary arteritis. Arterioscler Thromb Vasc Biol. 2015;35:1423-1433. doi: 10.1161/ATVBAHA.114.304846.
34. Persson EK, Scott CL, Mowat AM, Agace WW. Dendritic cell subsets in the intestinal lamina propria: ontogeny and function. Eur J Immunol. 2013;43:3098-3107. doi: 10.1002/eji.201343740.
35. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G, Quadroni M, Drexler SK, Tschopp J. Inflammasome activators induce interleukin-1 secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity. 2012;36:388-400. doi: 10.1016/j.immuni.2012.01.018.
36. Pasare C, Medzhitov R. Control of B-cell responses by toll-like receptors. Nature. 2005;438:364-368. doi: 10.1038/nature04267.
37. Takakura N, Huang XL, Naruse T, Hamaguchi I, Dumont DJ, Yancopoulos GD, Suda T. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity. 1998;9:677-686.
38. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene. 1992;7:1471-1480.
39. Dagvadorj J, Shimada K, Chen S, Jones HD, Tumurkhuu G, Zhang W, Wawrowsky KA, Crother TR, Arditi M. Lipopolysaccharide induces alveolar macrophage necrosis via CD14 and the P2X7 receptor leading to interleukin-1 release. Immunity. 2015;42:640-653. doi: 10.1016/j.immuni.2015.03.007.
40. Weng KP, Hsieh KS, Ho TY, Huang SH, Lai CR, Chiu YT, Huang SC, Lin CC, Hwang YT, Ger LP. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ J. 2010;74:544-551.
41. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-652. doi: 10.1038/nrd3800.
42. Dinarello CA. A clinical perspective of IL-1 as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203-1217. doi: 10.1002/eji.201141550.
43. Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910-1923. doi: 10.1161/CIRCULATIONAHA.113.003199.
44. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179-188. doi: 10.1038/nm.2279.
45. Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, Michelson K, Hunter JJ, Kantak SS. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis. 2011;216:313-320. doi: 10.1016/j.atherosclerosis.2011.02.026.
46. Maury CP, Salo E, Pelkonen P. Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med. 1988;319:1670-1671. doi: 10.1056/NEJM198812223192515.
47. Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child. 2006;91:847-851. doi: 10.1136/adc.2005.087437.
48. Leung DY, Cotran RS, Kurt-Jones E, Burns JC, Newburger JW, Pober JS. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 1989;2:1298-1302.
49. Suzuki H, Uemura S, Tone S, Iizuka T, Koike M, Hirayama K, Maeda J. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr. 1996;155:291-296.
50. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21:677-687. doi: 10.1038/nm.3893.
51. Freigang S, Ampenberger F, Weiss A, Kanneganti TD, Iwakura Y, Hersberger M, Kopf M. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1 and sterile vascular inflammation in atherosclerosis. Nat Immunol. 2013;14:1045-1053. doi: 10.1038/ni.2704.
52. Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer HD, Johansen P, Senti G, Contassot E, Bachmann MF, French LE, Oxenius A, Kündig TM. Inflammasome activation and IL-1 target IL-1 for secretion as opposed to surface expression. Proc Natl Acad Sci USA. 2011;108:18055-18060. doi: 10.1073/pnas.1109176108.
53. Kamari Y, Shaish A, Shemesh S, Vax E, Grosskopf I, Dotan S, White M, Voronov E, Dinarello CA, Apte RN, Harats D. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1. Biochem Biophys Res Commun. 2011;405:197-203. doi: 10.1016/j.bbrc.2011.01.008.
54. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, White MR, Dinarello CA, Apte RN. IL-1 and IL-1 recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187:4835-4843. doi: 10.4049/jimmunol.1102048.
55. Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, Rider P, Kaplanov I, Aychek T, Dinarello CA, Apte RN, Voronov E. Non-redundant properties of IL-1 and IL-1 during acute colon inflammation in mice. Gut. 2014;63:598-609. doi: 10.1136/gutjnl-2012-303329.
56. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720-3732. doi: 10.1182/blood-2010-07-273417.
57. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, Ling L, Wright VJ, Thalamuthu A, Odam M, Shimizu C, Burns JC, Levin M, Kuijpers TW, Hibberd ML; International Kawasaki Disease Genetics Consortium. A genome-wide association study identifies novel and functionally related susceptibility Loci for Kawasaki disease. PLoS Genet. 2009;5:e1000319. doi: 10.1371/journal.pgen.1000319.
58. Chang CJ, Kuo HC, Chang JS, et al; International Kawasaki Disease Genetics Consortium; Korean Kawasaki Disease Genetics Consortium; Taiwan Kawasaki Disease Genetics Consortium. Replication and metaanalysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility. PLoS One. 2013;8:e72037. doi: 10.1371/journal.pone.0072037.
59. Kuo HC, Hsu YW, Lo MH, Huang YH, Chien SC, Chang WC. Singlenucleotide polymorphism rs7251246 in ITPKC is associated with susceptibility and coronary artery lesions in Kawasaki disease. PLoS One. 2014;9:e91118. doi: 10.1371/journal.pone.0091118.
60. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40:35-42. doi: 10.1038/ng.2007.59.
61. Lou J, Xu S, Zou L, Zhong R, Zhang T, Sun Y, Lu X, Liu L, Li C, Wang L, Xiong G, Wang W, Gong F, Wu J. A functional polymorphism, rs28493229, in itpkc and risk of Kawasaki disease: an integrated metaanalysis. Mol Biol Rep 2012.
62. Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the nlrp3 inflammasome. Trends Immunol. 2014;35:253-261.
63. Alphonse MP, Duong TT, Shimizu C, Hoang LT, McCrindle BW, Franco A, Schurmans S, Philpott DJ, Hibberd ML, Burns JC, Kuijpers TW, Yeung RS. Abstract o.21: Inositol 1,4,5 triphosphate 3-kinase c regulates nlrp3 inflammasome activation in kawasaki disease. Circulation. 2015;131(Suppl 2):AO21-AO21.
64. Bonin PD, Fici GJ, Singh JP. Interleukin-1 promotes proliferation of vascular smooth muscle cells in coordination with PDGF or a monocyte derived growth factor. Exp Cell Res. 1989;181:475-482.
65. Sasu S, Beasley D. Essential roles of IkappaB kinases alpha and beta in serum-and IL-1-induced human VSMC proliferation. Am J Physiol Heart Circ Physiol. 2000;278:H1823-H1831.
66. Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, Owens GK. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest. 2012;122:70-79. doi: 10.1172/JCI43713.
67. Arditi M. Animal models for understanding Kawasaki disease. International Kawasaki Disease Symposium. 2015.
68. Johnson JL, Dwivedi A, Somerville M, George SJ, Newby AC. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol. 2011;31:e35-e44. doi: 10.1161/ATVBAHA. 111.225623.
69. Chua PK, Melish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol. 2003;10:308-314.
70. Hong YM, Jin HS, Park IS, Hong SJ. Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children. Heart Vessels. 2008;23:341-347. doi: 10.1007/s00380-008-1041-1.
71. Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, Sekine I. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol. 2001;125:340-344.
72. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, Garner H, Trouillet C, de Bruijn MF, Geissmann F, Rodewald HR. Tissueresident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547-551. doi: 10.1038/nature13989.
73. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11:723-737. doi: 10.1038/nri3073.
74. Kopf M, Schneider C, Nobs SP. The development and function of lungresident macrophages and dendritic cells. Nat Immunol. 2015;16:36-44. doi: 10.1038/ni.3052.
75. Chen Y, Li X, Boini KM, Pitzer AL, Gulbins E, Zhang Y, Li P-L. Endothelial nlrp3 inflammasome activation associated with lysosomal destabilization during coronary arteritis. Biochimica et biophysica acta. 2014.
76. Abe J-I, Berk BC. Athero-prone flow activation of the srebp2-nlrp3 inflammasome mediates focal atherosclerosis. Circulation. 2013;128:579-582.
77. Xiao H, Lu M, Lin TY, et al. Srebp2 activation of nlrp3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility. Circulation. 2013;128:632-642.
78. Xiang M, Shi X, Li Y, Xu J, Yin L, Xiao G, Scott MJ, Billiar TR, Wilson MA, Fan J. Hemorrhagic shock activation of NLRP3 inflammasome in lung endothelial cells. J Immunol. 2011;187:4809-4817.
79. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013-1022. doi: 10.1016/j.cell.2014.04.007.